FDA

FDA Reorg Establishes Office of Digital Transformation

By MedTech Intelligence Staff
No Comments
FDA

The agency has realigned information technology, data management and cybersecurity functions, and established a new office reporting directly to the FDA commissioner.

FDA is continuing on its efforts to prioritize prioritizing technology and data modernization with the establishment of a new Office of Digital Transformation. The office moves the agency’s information technology, data management and cybersecurity roles into a central office that reports directly to the FDA commissioner. The reorganization will also help FDA further streamline its data and IT management processes, reducing duplication of processes, and promote best practices, technological efficiencies and shared services in a strategic and secure way.

“Good data management, built into all of our work, ultimately helps us meet and advance the FDA’s mission to ensure safe and effective products for American families,” said Acting FDA Commissioner Janet Woodcock, M.D., in an FDA news release. “The agency began these efforts because, as a science-based agency that manages massive amounts of data to generate important decisions and information for the public, innovation is at the heart of what we do. By prioritizing data and information stewardship throughout all of our operations, the American public is better assured of the safety of the nation’s food, drugs, medical devices and other products that the FDA regulates in this complex world. This reorganization strengthens our commitment to protecting and promoting public health by improving our regulatory processes with a solid data foundation built in at every level.”

 

Related Articles

  • Pixabay Hearing Aid

    The final rule from the FDA establishes a new category of over-the-counter hearing aids, enabling consumers with perceived mild to moderate hearing impairment to purchase hearing aids directly from stores or online retailers.

  • Chris Fourment

    Chris Fourment, MD, Senior Vice President, Clinical Strategy at Iterative Health, who specializes in structuring clinical trial programs, discusses the new FDA guidance on decentralized clinical trials, and how DCTs can help spur health and research equity.

  • Rogers-Headshot

    Digital therapeutics (DTx) have the potential to lower healthcare costs and improve patient compliance, outcomes and access to care. In the first part of this two-article series we look at the current and potential applications for this growing sector of…

  • Rogers-Headshot

    The second part of this two-article series on digital therapeutics (DTx) sheds light on challenges faced by the companies in the DTx market and outlines hurdles that must be overcome to achieve success.

Leave a Reply

Your email address will not be published. Required fields are marked *